ZyVersa Therapeutics Short Long Term Debt Total Over Time
| ZVSA Stock | 1.03 0.04 3.74% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ZyVersa Therapeutics Performance and ZyVersa Therapeutics Correlation. ZyVersa |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 491.97 | Return On Assets (0.25) | Return On Equity (1.52) |
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Short Long Term Debt Total Analysis
Compare ZyVersa Therapeutics and related stocks such as Cns Pharmaceuticals, Effector Therapeutics, and VectivBio Holding Short Long Term Debt Total Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNSP | 121.8 K | 121.8 K | 121.8 K | 121.8 K | 121.8 K | 121.8 K | 121.8 K | 121.8 K | 316.9 K | 439.3 K | 439.3 K | 387.8 K | 410 K | 300.8 K | 362.4 K |
| IMMX | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 50 K | 50 K | 45 K | 42.8 K |
| HEPA | 10.4 K | 10.4 K | 10.4 K | 10.4 K | 10.4 K | 10.4 K | 10.4 K | 1.4 M | 1.4 M | 807.4 K | 752.2 K | 317 K | 53.6 K | 209 K | 360 K |
| ZURA | 355.6 K | 355.6 K | 355.6 K | 355.6 K | 355.6 K | 355.6 K | 355.6 K | 355.6 K | 355.6 K | 355.6 K | 355.6 K | 355.6 K | 355.6 K | 320 K | 284.5 K |
ZyVersa Therapeutics and related stocks such as Cns Pharmaceuticals, Effector Therapeutics, and VectivBio Holding Short Long Term Debt Total description
My Equities
My Current Equities and Potential Positions
| ZyVersa Therapeutics | ZVSA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New Jersey; U.S.A |
| Exchange | NASDAQ Exchange |
null 1.03
Check out ZyVersa Therapeutics Performance and ZyVersa Therapeutics Correlation. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
ZyVersa Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.